If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

You have been exercising, eating home-cooked meals, and have managed to cut out fried food and desserts from your diet for ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Cipla expands into CNS and weight management segments, focusing on patient needs and innovation for long-term value.

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said.